Page last updated: 2024-11-10

esculin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID5281417
CHEMBL ID482581
CHEBI ID4853
SCHEMBL ID2893
MeSH IDM0007736

Synonyms (105)

Synonym
BRD-K51742987-001-02-3
2h-1-benzopyran-2-one, 6-(.beta.-d-glucopyranosyloxy)-7-hydroxy-
aesculin
nsc-26665
KBIO1_000956
DIVK1C_000956
SDCCGMLS-0066653.P001
7-hydroxy-6-cumarinyl-glucosid
6-(beta-d-glucopyranosyloxy)-7-hydroxy-cumarin
ccris 5724
6-(beta-d-glucopyranosyloxy)-7-hydroxy-2h-1-benzopyran-2-one
aesculetin glukosid
2h-1-benzopyran-2-one, 6-(beta-d-glucopyranosyloxy)-7-hydroxy-
(-)-esculin
nsc 26665
einecs 208-517-5
7-hydroxy-6-glucosyloxy-2h-chromen
SPECTRUM_000361
SPECTRUM4_001923
IDI1_000956
NCGC00016491-01
cas-531-75-9
BCBCMAP01_000202
SPECTRUM5_000845
SMP1_000008
BSPBIO_002282
esculoside
C09264
esculin ,
531-75-9
SR-01000633930-1
KBIOGR_002266
KBIOSS_000841
KBIO2_003409
KBIO2_000841
KBIO2_005977
KBIO3_001502
SPBIO_000392
NINDS_000956
SPECTRUM3_000731
SPECTRUM2_000576
SPECTRUM1500901
HMS502P18
7-hydroxycoumarin-6-yl beta-d-glucopyranoside
HMS1921M16
CHEMBL482581
chebi:4853 ,
7-hydroxy-6-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-2-one
7-hydroxy-6-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-2h-chromen-2-one
A829428
7-hydroxy-6-[3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-chromen-2-one hydrate;esculin sesquihydrate
dtxcid5025318
tox21_110453
dtxsid7045318 ,
7-hydroxy-2-oxo-2h-chromen-6-yl beta-d-glucopyranoside
esculetin 6-o-glucoside
esculetin 6-beta-d-glucoside
7-hydroxy-6-glucosyloxy-2h-chromene
CCG-38501
1y1l18lqaf ,
venoplant
unii-1y1l18lqaf
6,7-dihydroxycoumarin-6-o-glucoside
aesculinum
6,7-dihydroxycoumarin 6-glucoside
AKOS015895151
S2258
esculoside [jan]
esculin [mi]
enallachrome
esculoside [who-dd]
bicolorin
escosyl
esculin [inci]
aesculinum [hpus]
6-(.beta.-d-glucopyranosyloxy)-7-hydroxy-2h-1-benzopyran-2-one
esculina
SCHEMBL2893
esculine
6-(.beta.-d-glucopyranosyloxy)-7-hydroxy-cumarin
esculetin 6-.beta.-d-glucoside
vitamin c2
crataegin
esculetin glukosid
7-hydroxy-6-(((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)-2h-chromen-2-one
SR-01000633930-3
bdbm50480261
schillerstoff
mfcd00006879
esculetin 6-b-d-glucoside
esculin, european pharmacopoeia (ep) reference standard
DB13155
7-hydroxy-6-((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yloxy)-2h-chromen-2-one
Q376432
aesculin (esculin)
BRD-K51742987-002-02-1
CS-0007892
HY-N0188
7-hydroxy-6-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy- 6-(hydroxymethyl)-2-tetrahydropyranyl]oxy}-2-chromenone
NCGC00094874-04
6-[(2s,3r,4s,5s,6r)-6-(hydroxymethyl)-3,4,5-tris(oxidanyl)oxan-2-yl]oxy-7-oxidanyl-chromen-2-one
7ou ,
EN300-116211
EX-A6781
Z1494829512

Research Excerpts

Overview

Esculin is a polyphenol with multiple bioactivities and poor lipophilicity. It has antibacterial, anti-inflammatory, anti‑allergy and skin protective effects. Esculin hydrolysis is a valuable test for the taxonomic classification of the family Enterobacteriaceae.

ExcerptReferenceRelevance
"Esculin is a polyphenol with multiple bioactivities and poor lipophilicity. "( Highly efficient whole-cell biosynthesis and cytotoxicity of esculin esters.
Hao, L; Lai, X; Lei, F; Li, X; Wu, H; Xin, X; Zhang, M; Zhao, G, 2021
)
2.31
"Esculin is a derivative of coumarin, which is also an active ingredient of ash bark, and has antibacterial, anti-inflammatory, anti‑allergy and skin protective effects. "( Esculin ameliorates cognitive impairment in experimental diabetic nephropathy and induces anti-oxidative stress and anti-inflammatory effects via the MAPK pathway.
Gao, Y; Li, J; Qin, S; Song, Y; Wang, X; Zhou, S, 2018
)
3.37
"Esculin hydrolysis is a valuable test for the taxonomic classification of the family Enterobacteriaceae."( The use of bile - esculin agar for the taxonomic classification of the family Enterobacteriaceae.
Edberg, SC; Pittman, S; Singer, JM, 1977
)
1.31
"Esculin hydrolysis is a useful test in the differentiation of both gram-positive and gram-negative bacteria covering a wide spectrum of aerobes, facultative anaerobes, and anaerobes. "( Rapid spot test for the determination of esculin hydrolysis.
Bottenbley, CJ; Edberg, SC; Gam, K; Singer, JM, 1976
)
1.96

Effects

Esculin has anti-diabetic effect, which is closely related to improving pancreas damage, promoting insulin release, and enhancing glucose homeostasis. Esculin and esculetin have been well separated within 9 min in a 40 cm long capillary at a separation voltage of 12 kV. Bile-esculin medium has been used for many years for the presumptive identification of group D Streptococcus.

ExcerptReferenceRelevance
"Esculin has anti-diabetic effect, which is closely related to improving pancreas damage, promoting insulin release, and enhancing glucose homeostasis."( The pharmacological and pharmacokinetic properties of esculin: A comprehensive review.
Lai, J; Li, CX; Li, JC; Liu, Y, 2022
)
1.69
"Esculin and esculetin have been well separated within 9 min in a 40 cm long capillary at a separation voltage of 12 kV using a 50 mM borate buffer (pH 9.2)."( Carbon nanotube/poly(ethylene-co-vinyl acetate) composite electrode for capillary electrophoretic determination of esculin and esculetin in Cortex Fraxini.
Chen, G; Chen, Z; Zhang, L, 2009
)
1.28
"Esculin agar has been found to be a simple, inexpensive, rapid, and reliable means to promote production of spores of inhibitor-sensitive clones of Bacillus subtilis strains ATCC 6051 and 6633 for use in the Guthrie bioassay screening tests for genetic metabolic disorders."( Simple, inexpensive, and rapid way to produce Bacillus subtilis spores for the Guthrie bioassay.
Clark, WA; Franklin, ML, 1981
)
1.71
"Bile-esculin medium has been used for many years for the presumptive identification of group D Streptococcus. "( The use of bile - esculin agar for the taxonomic classification of the family Enterobacteriaceae.
Edberg, SC; Pittman, S; Singer, JM, 1977
)
1.1
"Bile-esculin agar has been used for several years for the presumptive identification of group D streptococci. "( Use of bile-esculin agar for rapid differentiation of Enterobacteriaceae.
Lindell, SS; Quinn, P, 1975
)
1.15
"Esculin has been incorporated into both a medium and test with 20% bile for many years to differentiate Bacteroides from Fusobacterium organisms. "( Lack of constitutive beta-glucosidase (esculinase) in the genus Fusobacterium.
Bell, SR; Edberg, SC, 1985
)
1.98

Treatment

Pretreatment with esculin significantly reduced macroscopic and histopathological damage, gastric lesion index, and MPO activity in a dose-dependent manner. Pretreatment with scoparone and daphnetin produced the best protective effects.

ExcerptReferenceRelevance
"Treatment with esculin, prior to incubation with bioallethrin, led to significant restoration in all these parameters in an esculin concentration-dependent manner."( Esculin protects human blood cells from bioallethrin-induced toxicity: An ex vivo study.
Arif, A; Mahmood, R; Quds, R; Salam, S, 2023
)
2.69
"Treatment with esculin, scoparone and daphnetin produced the best protective effects. "( Antioxidant and intestinal anti-inflammatory effects of plant-derived coumarin derivatives.
Cestari, SH; da Silveira Chagas, A; de Almeida, LD; Di Stasi, LC; Luchini, AC; Rodrigues-Orsi, P; Seito, LN; Witaicenis, A, 2014
)
0.76
"Pretreatment with esculin significantly reduced macroscopic and histopathological damage, gastric lesion index, and MPO activity in a dose-dependent manner."( Gastroprotective effect of esculin on ethanol-induced gastric lesion in mice.
He, Z; Li, W; Liu, F; Niu, X; Wang, X; Wang, Y; Zhang, H; Zhi, W, 2017
)
1.08
"Pretreatment with esculin, the 6-glucoside of esculetin, was effective, but to a lesser extent."( Suppression of lipid hydroperoxide-induced oxidative damage to cellular DNA by esculetin.
Kaneko, T; Tahara, S; Takabayashi, F, 2003
)
0.64

Toxicity

ExcerptReferenceRelevance
"In plants potentially toxic compounds are ultimately deposited in the large central vacuole."( A herbicide antidote (safener) induces the activity of both the herbicide detoxifying enzyme and of a vacuolar transporter for the detoxified herbicide.
Amrhein, N; Dufaud, A; Gaillard, C; Kreuz, K; Martinoia, E; Tommasini, R, 1994
)
0.29
" And no patient appeared any adverse reaction in whole experiment."( [The clinical efficacy and safety study of Esculin and Digitalis glycosides Eye Drops in treating ametropic asthenopia].
Chu, RY; Jiang, J; Jiang, ZY; Ke, BL; Li, XX; Liu, YL; Qu, XM; Shen, NC; Yang, X; Yao, K; Zeng, J; Zhang, L; Zhao, PQ, 2010
)
0.62
"Bioallethrin, a household insecticide, is a member of the pyrethroid family and is known for its adverse effects on human health."( Esculin protects human blood cells from bioallethrin-induced toxicity: An ex vivo study.
Arif, A; Mahmood, R; Quds, R; Salam, S, 2023
)
2.35

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacokinetic profile of C as well as the metabolic 7-hydroxylation and glucuronidation found in the blood of the gerbil is similar to that found in man."( Pharmacokinetics of coumarin, 7-hydroxycoumarin and 7-hydroxycoumarin glucuronide in the blood and brain of gerbils following intraperitoneal administration of coumarin.
Hardt, TJ; Ritschel, WA, 1983
)
0.27
" After oral administration of 120 mg/kg, the mean Cmax values were 340."( HPLC Determination of Esculin and Esculetin in Rat Plasma for Pharmacokinetic Studies.
Kang, KS; Kim, IS; Rehman, SU; Yoo, HH, 2015
)
0.73
" The purpose of the review is to systematically review relevant studies on the pharmacological effects and pharmacokinetic characteristics of esculin to support its further application as therapeutic agents."( The pharmacological and pharmacokinetic properties of esculin: A comprehensive review.
Lai, J; Li, CX; Li, JC; Liu, Y, 2022
)
1.17

Compound-Compound Interactions

Nebulization therapy combined with meibomian gland massage appears to be more effective in treating clinical symptoms and signs of MGD than simply applying esculin and digitalis glycoside eye drops.

ExcerptReferenceRelevance
" Therefore, the aim of our study was to investigate the effect of simple coumarins (osthole, umbelliferone, esculin, and 4-hydroxycoumarin) combined with sorafenib (specific inhibitor of Raf (Rapidly Accelerated Fibrosarcoma) kinase) in programmed death induction in human glioblastoma multiforme (T98G) and anaplastic astrocytoma (MOGGCCM) cells lines."( Antiglioma Potential of Coumarins Combined with Sorafenib.
Jakubowicz-Gil, J; Langner, E; Maciejczyk, A; Rzeski, W; Skalicka-Woźniak, K; Sumorek-Wiadro, J; Zając, A, 2020
)
0.77
"To evaluate ocular surface status and corneal higher-order aberrations after a new ocular nebulization therapy combined with meibomian gland massage for the treatment of meibomian gland dysfunction (MGD)."( An investigation into the effects of ocular nebulization combined with meibomian gland massage on ocular surface status and corneal higher-order aberrations for the treatment of meibomian gland dysfunction.
Lin, F; Liu, H; Ma, L; Mao, X, 2022
)
0.72
"In terms of comfort and visual quality, nebulization therapy combined with meibomian gland massage to deliver azithromycin solution and esculin and digitalis glycoside eye drops appears to be more effective in treating clinical symptoms and signs of MGD than simply applying esculin and digitalis glycoside eye drops."( An investigation into the effects of ocular nebulization combined with meibomian gland massage on ocular surface status and corneal higher-order aberrations for the treatment of meibomian gland dysfunction.
Lin, F; Liu, H; Ma, L; Mao, X, 2022
)
0.92

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Fifty C57BL/6J mice were divided into five groups. The antiviral activity of esculin was stable in the aquacultural water for 2 days.

ExcerptRelevanceReference
"Fifty C57BL/6J mice were divided into five groups: control, model, low dosage esculin (oral, 20 mg/kg), high dosage esculin (oral, 40 mg/kg), and silybin (oral, 105 mg/kg)."( Esculin protects against methionine choline-deficient diet-induced non-alcoholic steatohepatitis by regulating the Sirt1/NF-
Chen, J; Chen, Z; Yang, XD; Yang, YY; Ye, L, 2021
)
2.29
" Considering that the antiviral activity of esculin was stable in the aquacultural water for 2 days, we evaluated the dosing pattern of continuous medication changes."( Antiviral activity of esculin against white spot syndrome virus: A new starting point for prevention and control of white spot disease outbreaks in shrimp seedling culture.
Chen, J; Hu, Y; Liu, L; Shan, LP; Zhang, X, 2022
)
1.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antioxidantA substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides.
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
beta-D-glucosideAny D-glucoside in which the anomeric centre has beta-configuration.
hydroxycoumarinAny coumarin carrying at least one hydroxy substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
esculetin modification219
superpathway of scopolin and esculin biosynthesis127
esculetin modification221
superpathway of scopolin and esculin biosynthesis131

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AR proteinHomo sapiens (human)Potency8.54380.000221.22318,912.5098AID743035; AID743036; AID743053; AID743063
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency10.20960.000214.376460.0339AID720691; AID720692; AID720719
estrogen nuclear receptor alphaHomo sapiens (human)Potency9.79180.000229.305416,493.5996AID743069; AID743075; AID743077; AID743078
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency10.27740.001019.414170.9645AID743094; AID743140
Cellular tumor antigen p53Homo sapiens (human)Potency8.50160.002319.595674.0614AID651631; AID720552
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Macrophage migration inhibitory factorHomo sapiens (human)IC50 (µMol)160.00000.03803.09109.8000AID1877334
Macrophage migration inhibitory factorHomo sapiens (human)Ki143.00000.03802.22565.5500AID1877338
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (157)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
prostaglandin biosynthetic processMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of cytokine productionMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of mature B cell apoptotic processMacrophage migration inhibitory factorHomo sapiens (human)
inflammatory responseMacrophage migration inhibitory factorHomo sapiens (human)
cell surface receptor signaling pathwayMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of cell population proliferationMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of gene expressionMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of protein kinase A signalingMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of macrophage chemotaxisMacrophage migration inhibitory factorHomo sapiens (human)
carboxylic acid metabolic processMacrophage migration inhibitory factorHomo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of cell migrationMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of B cell proliferationMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of lipopolysaccharide-mediated signaling pathwayMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of tumor necrosis factor productionMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of myeloid cell apoptotic processMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of phosphorylationMacrophage migration inhibitory factorHomo sapiens (human)
regulation of macrophage activationMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of apoptotic processMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of DNA damage response, signal transduction by p53 class mediatorMacrophage migration inhibitory factorHomo sapiens (human)
innate immune responseMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of fibroblast proliferationMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationMacrophage migration inhibitory factorHomo sapiens (human)
positive chemotaxisMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of protein metabolic processMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of prostaglandin secretion involved in immune responseMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of myeloid leukocyte cytokine production involved in immune responseMacrophage migration inhibitory factorHomo sapiens (human)
protein homotrimerizationMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of arachidonic acid secretionMacrophage migration inhibitory factorHomo sapiens (human)
cellular senescenceMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of chemokine (C-X-C motif) ligand 2 productionMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of cellular senescenceMacrophage migration inhibitory factorHomo sapiens (human)
detection of chemical stimulus involved in sensory perception of bitter tasteTaste receptor type 2 member 16Homo sapiens (human)
G protein-coupled receptor signaling pathwayTaste receptor type 2 member 16Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (41)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
protease bindingMacrophage migration inhibitory factorHomo sapiens (human)
dopachrome isomerase activityMacrophage migration inhibitory factorHomo sapiens (human)
cytokine activityMacrophage migration inhibitory factorHomo sapiens (human)
cytokine receptor bindingMacrophage migration inhibitory factorHomo sapiens (human)
protein bindingMacrophage migration inhibitory factorHomo sapiens (human)
chemoattractant activityMacrophage migration inhibitory factorHomo sapiens (human)
identical protein bindingMacrophage migration inhibitory factorHomo sapiens (human)
phenylpyruvate tautomerase activityMacrophage migration inhibitory factorHomo sapiens (human)
G protein-coupled receptor activityTaste receptor type 2 member 16Homo sapiens (human)
protein bindingTaste receptor type 2 member 16Homo sapiens (human)
bitter taste receptor activityTaste receptor type 2 member 16Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (30)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
extracellular regionMacrophage migration inhibitory factorHomo sapiens (human)
extracellular spaceMacrophage migration inhibitory factorHomo sapiens (human)
nucleoplasmMacrophage migration inhibitory factorHomo sapiens (human)
cytoplasmMacrophage migration inhibitory factorHomo sapiens (human)
cytosolMacrophage migration inhibitory factorHomo sapiens (human)
plasma membraneMacrophage migration inhibitory factorHomo sapiens (human)
cell surfaceMacrophage migration inhibitory factorHomo sapiens (human)
vesicleMacrophage migration inhibitory factorHomo sapiens (human)
secretory granule lumenMacrophage migration inhibitory factorHomo sapiens (human)
extracellular exosomeMacrophage migration inhibitory factorHomo sapiens (human)
ficolin-1-rich granule lumenMacrophage migration inhibitory factorHomo sapiens (human)
extracellular spaceMacrophage migration inhibitory factorHomo sapiens (human)
endoplasmic reticulumTaste receptor type 2 member 16Homo sapiens (human)
trans-Golgi networkTaste receptor type 2 member 16Homo sapiens (human)
plasma membraneTaste receptor type 2 member 16Homo sapiens (human)
external side of plasma membraneTaste receptor type 2 member 16Homo sapiens (human)
membraneTaste receptor type 2 member 16Homo sapiens (human)
membraneTaste receptor type 2 member 16Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (49)

Assay IDTitleYearJournalArticle
AID683689Cytotoxicity against human U138MG cells incubated for 48 hrs by MTT assay2012European journal of medicinal chemistry, Nov, Volume: 57Selective cytotoxicity and apoptosis induction in glioma cell lines by 5-oxygenated-6,7-methylenedioxycoumarins from Pterocaulon species.
AID1850977Binding affinity to human 1BNA double stranded DNA assessed as change in melting temperature at 20 uM at pH 7.4 by FRET assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID1850990Displacement of thiazole orange from human 1BNA double stranded DNA at 10 equiv. at pH 7.4 by fluorescent intercalator displacement assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID683688Cytotoxicity against rat C6 cells incubated for 48 hrs by MTT assay2012European journal of medicinal chemistry, Nov, Volume: 57Selective cytotoxicity and apoptosis induction in glioma cell lines by 5-oxygenated-6,7-methylenedioxycoumarins from Pterocaulon species.
AID1877333Inhibition of inhibition of MIF tautomerase (unknown origin) in MIF-induced mouse RAW264.7 cells assessed as reduction in cell migration relative to control2022Bioorganic & medicinal chemistry letters, 01-01, Volume: 55Repurposing old drugs as novel inhibitors of human MIF from structural and functional analysis.
AID1850978Displacement of thiazole orange from human telomeric IKF1 G4 quadruplex DNA at 10 equiv. at pH 7.4 by fluorescent intercalator displacement assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID91568Percentage inhibition was obtained by performing in vitro assay on purified recombinant integrase by strand transfer method at 100 micro g/mL (experiment 1)1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Discovery of HIV-1 integrase inhibitors by pharmacophore searching.
AID1877335Reversal inhibition of MIF tautomerase (unknown origin) at 0.5 mM using 4-HPP as substrate preincubated for 30 min followed by 100 fold dilution by dilution assay2022Bioorganic & medicinal chemistry letters, 01-01, Volume: 55Repurposing old drugs as novel inhibitors of human MIF from structural and functional analysis.
AID1850984Displacement of thiazole orange from human ILPR G4 quadruplex DNA at 10 equiv. at pH 7.4 by fluorescent intercalator displacement assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID397122Inhibition of HIV1 RT
AID1850972Binding affinity to human telomeric 1ELN i-motif DNA assessed as change in melting temperature at 20 uM at pH 7.4 by FRET assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID1850982Displacement of thiazole orange from human telomeric 1ELN i-motif DNA at 10 equiv. at pH 5.5 by fluorescent intercalator displacement assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID1850986Displacement of thiazole orange from human ILPR i-motif DNA at 10 equiv. at pH 7.4 by fluorescent intercalator displacement assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID1850988Displacement of thiazole orange from human ILPR i-motif DNA at 10 equiv. at pH 5.5 by fluorescent intercalator displacement assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID1850975Binding affinity to human ILPR i-motif DNA assessed as change in melting temperature at 20 uM at pH 7.4 by FRET assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID1877338Inhibition of MIF tautomerase (unknown origin) using 4-HPP as substrate preincubated for 1 hr followed by substrate addition by Lineweaver-Burk plot anlysis2022Bioorganic & medicinal chemistry letters, 01-01, Volume: 55Repurposing old drugs as novel inhibitors of human MIF from structural and functional analysis.
AID1850971Binding affinity to human telomeric IKF1 G4 quadruplex DNA assessed as change in melting temperature at 20 uM at pH 7.4 by FRET assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID1248399Inhibition of alpha-amylase (unknown origin) relative to control2015Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20
From carbohydrates to drug-like fragments: Rational development of novel α-amylase inhibitors.
AID1370495Inhibition of Saccharomyces cerevisiae alpha-glucosidase using p-nitro-phenyl-alpha-D-glucopyranoside as substrate preincubated with enzyme followed by substrate addition measured after 10 mins for every 2.5 to 5 mins2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Chemical constituents from Taraxacum officinale and their α-glucosidase inhibitory activities.
AID1850976Binding affinity to human ILPR i-motif DNA assessed as change in melting temperature at 20 uM at pH 5.5 by FRET assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID1877340Non-competitive inhibition of MIF tautomerase (unknown origin) using 4-HPP as substrate preincubated for 1 hr followed by substrate addition by Lineweaver-Burk plot anlysis2022Bioorganic & medicinal chemistry letters, 01-01, Volume: 55Repurposing old drugs as novel inhibitors of human MIF from structural and functional analysis.
AID336478Inhibition of COX2 at 100 uM by scintillation proximity assay2002Journal of natural products, Nov, Volume: 65, Issue:11
Screening of ubiquitous plant constituents for COX-2 inhibition with a scintillation proximity based assay.
AID1850980Displacement of thiazole orange from human telomeric 1ELN i-motif DNA at 10 equiv. at pH 7.4 by fluorescent intercalator displacement assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID1877336Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability up to 100 uM by CCK8 assay2022Bioorganic & medicinal chemistry letters, 01-01, Volume: 55Repurposing old drugs as novel inhibitors of human MIF from structural and functional analysis.
AID1850973Binding affinity to human telomeric 1ELN i-motif DNA assessed as change in melting temperature at 20 uM at pH 5.5 by FRET assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID1850987Displacement of thiazole orange from human ILPR i-motif DNA at 100 equiv. at pH 7.4 by fluorescent intercalator displacement assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID1370496Inhibition of Saccharomyces cerevisiae alpha-glucosidase using p-nitro-phenyl-alpha-D-glucopyranoside as substrate at 200 uM preincubated with enzyme followed by substrate addition measured after 10 mins for every 2.5 to 5 mins relative to control2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Chemical constituents from Taraxacum officinale and their α-glucosidase inhibitory activities.
AID91569Percentage inhibition was obtained by performing in vitro assay on purified recombinant integrase by strand transfer method at 100 micro g/mL (experiment 2)1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Discovery of HIV-1 integrase inhibitors by pharmacophore searching.
AID1850989Displacement of thiazole orange from human ILPR i-motif DNA at 100 equiv. at pH 5.5 by fluorescent intercalator displacement assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID91565Percentage inhibition was obtained by performing in vitro assay on purified recombinant integrase by 3''-processing method at 100 micro g/mL (experiment 2)1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Discovery of HIV-1 integrase inhibitors by pharmacophore searching.
AID1877334Inhibition of MIF tautomerase (unknown origin) using 4-HPP as substrate preincubated for 1 hr followed by substrate addition2022Bioorganic & medicinal chemistry letters, 01-01, Volume: 55Repurposing old drugs as novel inhibitors of human MIF from structural and functional analysis.
AID1850979Displacement of thiazole orange from human telomeric IKF1 G4 quadruplex DNA at 100 equiv. at pH 7.4 by fluorescent intercalator displacement assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID126220Compound was tested for its inhibitory effect on MAO-A ( Monoamine Oxidase) at 100 uM2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Inhibition of monoamine oxidases by functionalized coumarin derivatives: biological activities, QSARs, and 3D-QSARs.
AID1850991Displacement of thiazole orange from human 1BNA double stranded DNA at 100 equiv. at pH 7.4 by fluorescent intercalator displacement assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID1850985Displacement of thiazole orange from human ILPR G4 quadruplex DNA at 100 equiv. at pH 7.4 by fluorescent intercalator displacement assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID1850983Displacement of thiazole orange from human telomeric 1ELN i-motif DNA at 100 equiv. at pH 5.5 by fluorescent intercalator displacement assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID1877332Potency index ratio of ISO-1 IC50 to test compound IC50 for inhibition of MIF tautomerase (unknown origin) using 4-HPP as substrate2022Bioorganic & medicinal chemistry letters, 01-01, Volume: 55Repurposing old drugs as novel inhibitors of human MIF from structural and functional analysis.
AID1850981Displacement of thiazole orange from human telomeric 1ELN i-motif DNA at 100 equiv. at pH 7.4 by fluorescent intercalator displacement assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID1850974Binding affinity to human ILPR G4 quadruplex DNA assessed as change in melting temperature at 20 uM at pH 7.4 by FRET assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID127175Compound was tested for its inhibitory effect on MAO-B ( Monoamine Oxidase) at 100 uM2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Inhibition of monoamine oxidases by functionalized coumarin derivatives: biological activities, QSARs, and 3D-QSARs.
AID91564Percentage inhibition was obtained by performing in vitro assay on purified recombinant integrase by 3''-processing method at 100 micro g/mL (experiment 1)1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Discovery of HIV-1 integrase inhibitors by pharmacophore searching.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (334)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990121 (36.23)18.7374
1990's39 (11.68)18.2507
2000's61 (18.26)29.6817
2010's80 (23.95)24.3611
2020's33 (9.88)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 64.80

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index64.80 (24.57)
Research Supply Index5.87 (2.92)
Research Growth Index4.63 (4.65)
Search Engine Demand Index110.39 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (64.80)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (1.72%)5.53%
Reviews4 (1.15%)6.00%
Case Studies4 (1.15%)4.05%
Observational0 (0.00%)0.25%
Other335 (95.99%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]